JP2017119710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017119710A5 JP2017119710A5 JP2017061022A JP2017061022A JP2017119710A5 JP 2017119710 A5 JP2017119710 A5 JP 2017119710A5 JP 2017061022 A JP2017061022 A JP 2017061022A JP 2017061022 A JP2017061022 A JP 2017061022A JP 2017119710 A5 JP2017119710 A5 JP 2017119710A5
- Authority
- JP
- Japan
- Prior art keywords
- psychotropic drug
- flecainide
- group
- modafinil
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004089 psychotropic agent Substances 0.000 claims 11
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims 8
- 229960000449 Flecainide Drugs 0.000 claims 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 8
- YFGHCGITMMYXAQ-UHFFFAOYSA-N Modafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 6
- 229960001165 modafinil Drugs 0.000 claims 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 4
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 4
- 229940025084 Amphetamine Drugs 0.000 claims 4
- 102100013818 HCRT Human genes 0.000 claims 4
- 101710023151 HCRT Proteins 0.000 claims 4
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 4
- 229960001344 Methylphenidate Drugs 0.000 claims 4
- 229960002734 amfetamine Drugs 0.000 claims 4
- 229960004823 armodafinil Drugs 0.000 claims 4
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 claims 4
- 229960001948 caffeine Drugs 0.000 claims 4
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229960000299 mazindol Drugs 0.000 claims 4
- -1 pitrisant Chemical compound 0.000 claims 4
- 229960003928 sodium oxybate Drugs 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 3
- 230000003291 dopaminomimetic Effects 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 230000003371 gabaergic Effects 0.000 claims 2
- 230000000848 glutamatergic Effects 0.000 claims 2
- 230000000742 histaminergic Effects 0.000 claims 2
- 230000000862 serotonergic Effects 0.000 claims 2
- JUUFBMODXQKSTD-UHFFFAOYSA-N Flupirtine Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960003667 flupirtine Drugs 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 200000000019 wound Diseases 0.000 claims 1
Claims (10)
- ＧＡＢＡ作動性、ドーパミン作動性、ノルエピネフリン作動性、セロトニン作動性、ヒスタミン作動性、及びグルタミン酸作動性エフェクター、並びにヒポクレチン／オレキシン系に対して効果を有するもの、からなる群から選択される向精神薬の効果の増強における使用のためのフレカイニド。
- 前記向精神薬の効き目、及び／又はその安全性、及び／又は作用の持続時間を増加させるための、請求項１に記載のフレカイニド。
- 前記向精神薬は、カフェイン、マジンドール、ナトリウムオキシベート、ピトリサント、アンフェタミン、メチルフェニデート、（Ｒ）−（β−アミノベンゼンプロピル）カルバミン酸一塩酸塩、モダフィニル及びアルモダフィニルからなる群で選択される、請求項１又は２に記載のフレカイニド。
- カフェイン、マジンドール、ナトリウムオキシベート、ピトリサント、アンフェタミン、メチルフェニデート、（Ｒ）−（β−アミノベンゼンプロピル）カルバミン酸一塩酸塩、モダフィニル及びアルモダフィニルからなる群で選択される向精神薬の効果、好ましくは、好記憶性（promnesiant）効果及び/又は覚醒効果、の増強のための請求項１〜３のいずれか一項に記載のフレカイニド。
- カフェイン、マジンドール、ナトリウムオキシベート、ピトリサント、アンフェタミン、メチルフェニデート、（Ｒ）−（β−アミノベンゼンプロピル）カルバミン酸一塩酸塩、モダフィニル及びアルモダフィニルからなる群で選択される向精神薬の効き目、及び／又は作用の持続時間を増加させるための、請求項１〜４のいずれか一項に記載のフレカイニド。
- 前記向精神薬がモダフィニルである、請求項１〜５のいずれか一項に記載のフレカイニド。
- フレカイニドと少なくとも１つの向精神薬とを含む治療用組成物であって、前記向精神薬がフルピルチンではない、治療用組成物。
- 前記向精神薬が、ＧＡＢＡ作動性、ドーパミン作動性、ノルエピネフリン作動性、セロトニン作動性、ヒスタミン作動性、及びグルタミン酸作動性エフェクター、並びにヒポクレチン／オレキシン系に対して効果を有するもの、からなる群から選択される、請求項７に記載の治療用組成物。
- 前記向精神薬が、カフェイン、マジンドール、ナトリウムオキシベート、ピトリサント、アンフェタミン、メチルフェニデート、（Ｒ）−（β−アミノベンゼンプロピル）カルバミン酸一塩酸塩、モダフィニル及びアルモダフィニルからなる群で選択される向精神薬、好ましくはモダフィニル、である、請求項７又は８に記載の治療用組成物。
- 傷、偏頭痛、感染症、薬剤誘発性肝障害、化学療法剤によって誘導される細胞毒性及び虚血からなる群から選択される疾患の治療における使用のためのフレカイニド。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306074.9 | 2013-07-24 | ||
| EP13306074 | 2013-07-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Division JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018233114A Division JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017119710A JP2017119710A (ja) | 2017-07-06 |
| JP2017119710A5 true JP2017119710A5 (ja) | 2017-08-17 |
| JP6453931B2 JP6453931B2 (ja) | 2019-01-16 |
Family
ID=48900920
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Expired - Fee Related JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
| JP2017061022A Expired - Fee Related JP6453931B2 (ja) | 2013-07-24 | 2017-03-27 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
| JP2018233114A Expired - Fee Related JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528540A Expired - Fee Related JP6192830B2 (ja) | 2013-07-24 | 2014-07-24 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018233114A Expired - Fee Related JP6694497B2 (ja) | 2013-07-24 | 2018-12-13 | 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9750734B2 (ja) |
| EP (2) | EP3024458B1 (ja) |
| JP (3) | JP6192830B2 (ja) |
| KR (2) | KR20170068629A (ja) |
| CN (1) | CN105579041B (ja) |
| AU (1) | AU2014295030B2 (ja) |
| BR (1) | BR112016001446A8 (ja) |
| CA (2) | CA2919140C (ja) |
| DK (1) | DK3024458T3 (ja) |
| ES (1) | ES2661647T3 (ja) |
| HR (1) | HRP20180487T1 (ja) |
| HU (1) | HUE037122T2 (ja) |
| IL (2) | IL243746A (ja) |
| MX (2) | MX365782B (ja) |
| PL (1) | PL3024458T3 (ja) |
| PT (1) | PT3024458T (ja) |
| RU (2) | RU2661026C2 (ja) |
| TR (1) | TR201802302T4 (ja) |
| WO (1) | WO2015011246A1 (ja) |
| ZA (1) | ZA201601146B (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6720301B2 (ja) * | 2015-07-15 | 2020-07-08 | テラネクス | 脳のヘミチャネルを遮断するためのアミトリプチリンの使用及びその効果をｉｎ ｖｉｖｏで増強する方法 |
| WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
| CA3097378A1 (en) * | 2018-04-16 | 2019-10-24 | Alsar Ltd Partnership | Compositions and methods for sustained release of flecainide |
| WO2019240997A1 (en) * | 2018-06-11 | 2019-12-19 | Indiana University Research And Technology Corporation | Methods for assessment and early detection of stress, selecting and monitoring treatment, and new use for drugs |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| EP3593822A1 (en) | 2018-07-13 | 2020-01-15 | Theranexus | Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri) |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11021410B2 (en) * | 2018-12-10 | 2021-06-01 | Purdue Research Foundation | Layer-wise agglomerated urea granules |
| US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| WO2021025985A1 (en) * | 2019-08-02 | 2021-02-11 | Praxis Precision Medicines, Inc. | Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression |
| CN111018694A (zh) * | 2019-12-12 | 2020-04-17 | 贵州省欣紫鸿药用辅料有限公司 | 一种氟卡尼的生产方法 |
| CN116096900A (zh) * | 2020-05-13 | 2023-05-09 | 阿库斯股份有限公司 | 用于治疗gjb2相关听力损失的组合物和方法 |
| KR102390194B1 (ko) * | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| WO2022170081A1 (en) * | 2021-02-05 | 2022-08-11 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001253825A (ja) | 2000-03-13 | 2001-09-18 | Masahiko Ichimada | 帯状疱疹後神経痛用鎮痛剤 |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| EP1951262A4 (en) * | 2005-11-21 | 2010-09-15 | Univ Alabama | METHODS USING SMALL MOLECULE COMPOUNDS FOR NEUROPROTECTION PURPOSES |
| CA2669832A1 (en) * | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
| FR2935611B1 (fr) * | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| WO2012042541A2 (en) | 2010-09-30 | 2012-04-05 | Council Of Scientific & Industrial Research | Method for predicting and modeling anti-psychotic activity using virtual screening model |
| US20130096067A1 (en) | 2011-09-14 | 2013-04-18 | Norbert Perrimon | Drosophila tumor stem cell model and uses thereof |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
-
2014
- 2014-07-24 RU RU2016105971A patent/RU2661026C2/ru active
- 2014-07-24 EP EP14742249.7A patent/EP3024458B1/en active Active
- 2014-07-24 JP JP2016528540A patent/JP6192830B2/ja not_active Expired - Fee Related
- 2014-07-24 KR KR1020177015674A patent/KR20170068629A/ko not_active IP Right Cessation
- 2014-07-24 CA CA2919140A patent/CA2919140C/en active Active
- 2014-07-24 AU AU2014295030A patent/AU2014295030B2/en not_active Ceased
- 2014-07-24 MX MX2016001049A patent/MX365782B/es active IP Right Grant
- 2014-07-24 CA CA2997282A patent/CA2997282A1/en not_active Abandoned
- 2014-07-24 PT PT147422497T patent/PT3024458T/pt unknown
- 2014-07-24 RU RU2018122564A patent/RU2018122564A/ru not_active Application Discontinuation
- 2014-07-24 HU HUE14742249A patent/HUE037122T2/hu unknown
- 2014-07-24 BR BR112016001446A patent/BR112016001446A8/pt not_active Application Discontinuation
- 2014-07-24 EP EP17203646.9A patent/EP3308785A3/en not_active Withdrawn
- 2014-07-24 CN CN201480051866.3A patent/CN105579041B/zh active Active
- 2014-07-24 PL PL14742249T patent/PL3024458T3/pl unknown
- 2014-07-24 US US14/907,221 patent/US9750734B2/en active Active
- 2014-07-24 WO PCT/EP2014/065975 patent/WO2015011246A1/en active Application Filing
- 2014-07-24 TR TR2018/02302T patent/TR201802302T4/tr unknown
- 2014-07-24 KR KR1020167004739A patent/KR101754045B1/ko active IP Right Grant
- 2014-07-24 DK DK14742249.7T patent/DK3024458T3/en active
- 2014-07-24 ES ES14742249.7T patent/ES2661647T3/es active Active
-
2016
- 2016-01-21 IL IL243746A patent/IL243746A/en active IP Right Grant
- 2016-01-22 MX MX2019006878A patent/MX2019006878A/es unknown
- 2016-02-19 ZA ZA2016/01146A patent/ZA201601146B/en unknown
-
2017
- 2017-03-27 JP JP2017061022A patent/JP6453931B2/ja not_active Expired - Fee Related
- 2017-08-03 US US15/667,999 patent/US20180028519A1/en not_active Abandoned
- 2017-08-29 IL IL254210A patent/IL254210B/en unknown
-
2018
- 2018-03-26 HR HRP20180487TT patent/HRP20180487T1/hr unknown
- 2018-09-21 US US16/138,641 patent/US10639301B2/en not_active Expired - Fee Related
- 2018-12-13 JP JP2018233114A patent/JP6694497B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017119710A5 (ja) | ||
| RU2018122564A (ru) | Применение флекаинида в качестве антиконнексинового средства и способ потенцирования эффектов психотропных лекарственных средств | |
| HRP20210241T1 (hr) | Derivat policikličkog piridona protiv gripe i njegov predlijek | |
| AR125321A2 (es) | Compuesto cristalino, método de preparación y composición que lo comprende | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| MD3377488T2 (ro) | Compuși heterociclici ca imunomodulatori | |
| FI3692040T3 (fi) | Kemiallisia yhdisteitä | |
| JP2016515561A5 (ja) | ||
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| JP2018184433A5 (ja) | ||
| JP2017537936A5 (ja) | ||
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| JP2013510144A5 (ja) | ||
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| WO2017220042A3 (zh) | 氨力农的药物组合物及其在高血压治疗中的应用 | |
| JP2016537338A5 (ja) | ||
| MD3359146T2 (ro) | Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală | |
| WO2016112875A3 (zh) | 二联苯衍生物及其应用 | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| CL2021001968A1 (es) | Sales de sulcardina | |
| JP2020527138A5 (ja) | ||
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru |